Douglas Flora, President-Elect at Association of Cancer Care Centers, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, shared on LinkedIn:
“Cancer care is heading into its most disruptive decade. Demand is rising, the oncology workforce can’t keep pace and reimbursement pressure continues to build.
At the same time, the therapies reshaping the field are outrunning the systems meant to deliver them.
Fewer than 2 in 10 eligible patients access chimeric antigen receptor T-cell, or CAR-T, therapy today, despite a clear FDA pathway.
The next wave is already in motion for first approvals by 2030, including autoimmune applications, in vivo engineering and off-the-shelf cell therapies. Health systems that wait to build readiness risk negotiating from behind.
In this Becker’s webinar, I’ll be joining Premiere’s Kelley D. Simpson to outline what leaders and boards need to see now and what separates the systems that turn access into outcomes.
Learnings include:
- Why readiness, not regulation, is limiting CAR-T access, and what systems that convert access into outcomes do differently.
- How CAR-T’s move into community and outpatient settings, along with autoimmune and in vivo therapies, will change what cancer programs must be prepared to deliver.
- What a new multisystem cancer collaborative will tackle first across workforce, reimbursement and site of care, and how health systems can get involved early.”
You can also read: